 GT Biopharma Inc NASDAQ: GTBP has reported updated interim data from Phase 12 clinical trial, evaluating the Companys lead candidate, GTB-3550, in high-risk myelodysplastic syndromes MDS and refractoryrelapsed acute myeloid leukemia AML. To date, nine patients have been enrolled in the trial. 